Skip to main content
. 2015 Feb 9;33(17):1889–1894. doi: 10.1200/JCO.2014.56.2736

Fig 1.

Fig 1.

Primary analysis of pooled overall survival (OS) data. Individual patient data were pooled from 10 prospective trials and two retrospective, observational studies of ipilimumab in metastatic melanoma (n = 1,861). Median OS was 11.4 months (95% CI, 10.7 to 12.1 months) with a 3-year survival rate of 22% (95% CI, 20% to 24%). Crosses indicate censored patients.